AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
LabGenius Therapeutics has announced a new collaboration with Sanofi to optimize multiple AI/ML-driven antibody programs. The collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in NANOBODY molecules to co-optimize proteins for therapeutic properties. The partnership aims to improve outcomes for patients and follows the success of their first collaboration.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet